| 1 |
陆再英,钟南山.内科学[M]北京:人民卫生出版社,2008:567.
|
| 2 |
中国医师协会肾内科医师分会肾性贫血诊断和治疗共识专家组.肾性贫血诊断与治疗中国专家共识(2014 修订版)[J].中华肾脏病杂志,2014,30(9):712-716.
|
| 3 |
Lee YT, Chiu HC, Su HM,et al. Lower hemoglobin concentrations and subsequent decline in kidney function in an apparently healthy population aged 60 year and older [J]. Clin Chim Acta, 2008,389:25-30.
|
| 4 |
Port FK, Pisoni RL, Bommer J, et al. Improving outcomes for dialysis patients in the international dialysis outcomes and practice patterns study. Clin J Am Soc Nephrol,2006,1(2):246-255.
|
| 5 |
Portolés J, López-Gómez JM, Aljama P. A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients:The MAR Study [J]. Nephrol Dial Transplant,2007,22(2):500-507.
|
| 6 |
Locatelli F, Vecchio L,Pozzoni P. Anemia and cardiovascular risk:the lesson of the CREATE Trial [J]. J Am Soc Nephrol,2006,17(12 Suppl 3): S262-S266.
|
| 7 |
Goldsmith D,Covic A. Time to Reconider Evidence for Anaemia Treatment(TREAT) = Essential Safety Arguments (ESA) [J].Nephrol Dial Transplant,2010,25(6):1734-1737.
|
| 8 |
Regidor DL,Kopple JD,Kovesdy CP. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients [J]. J Am Soc Nephrol,2006,17(4):1181-1191.
|
| 9 |
McMurray JJV, Parfrey PS. KDIGO Clinical Practice Guideline Working Group. KDIGO clinical practice guideline for anemia in chronic kidney disease [J]. Kidney Int,2012,2( Suppl 4):279-335.
|
| 10 |
Unger EF, Thompson AM, Blank MJ, et al. Erythropoiesisstimulating agents--time for a reevaluation [J]. N Engl J Med,2010,362(3):189-192.
|
| 11 |
Loughnan A, Ali GR, Abeygunasekara SC. Comparison of the therapeutic efficacy of epoetin beta and epoetin alfa in maintenance phase hemodialysis patients [J]. Renal Failure, 2011, 33(3):373-375.
|
| 12 |
Servilla KS, Singh AK, Hunt WC, et al. Anemia management and association of race with mortality and hospitalization in a large notfor-profit dialysis organization [J]. Am J Kidney Dis, 2009, 54(3):498-510.
|
| 13 |
Zhang Y, Thamer M, Kaufman JS, et al. High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes[J]. Kidney Int,2011,80(6):663-669.
|
| 14 |
Lestz RM, Fivush BA, Atkinson MA. Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis [J]. Pediatr Nephrol,2014,29(10):2021-2028.
|
| 15 |
Vaziri ND, Zhou XJ. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease [J]. Nephrol Dial Transplant,2009,24(4):1082-1088.
|
| 16 |
U.S. Food and Drug Administration. FDA modifies dosing recommendations for Erythropoiesis-Stimulating Agents [EB/OL].[2011-06-27]. http: / /www. fda. gov /newsevents /newsroom /pressannouncements/ucm.260670.htm.
|
| 17 |
Sinsakul M, Rodby R, Umanath K, el at. Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data [J]. Expert Rev Clin Pharmacol, 2014, 7(6):705-710.
|
| 18 |
Schwenk MH. Ferumoxytol:a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease [J]. Pharmacotherapy,2010,30(1):70-79.
|
| 19 |
Qunibi WY1, Martinez C, Smith M, et al. A randomized controlled trial comparing intravenous ferriccarboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients[J]. Nephrol Dial Transplant,2011,26(5):1599-1607.
|
| 20 |
林攀,刘中华,邹建洲, 等. 上海市透析患者贫血治疗现况调查[J].肾脏病与透析肾移植杂志,2011,20(4):332-337.
|
| 21 |
Bailie GR. Comparison of rates of reported adverse events associated with i.v. iron products in the United States [J]. Am J Health Syst Pharm,2012,69(4):310-320.
|